scholarly article | Q13442814 |
P2093 | author name string | Koichi Furukawa | |
Graham M O'Hanlon | |||
Hugh J Willison | |||
Jaap J Plomp | |||
Roland W M Bullens | |||
Keiko Furukawa | |||
Peter C Molenaar | |||
Eric Wagner | |||
P2860 | cites work | An Unusual Variant of Acute Idiopathic Polyneuritis (Syndrome of Ophthalmoplegia, Ataxia and Areflexia) | Q22250915 |
Functional rafts in cell membranes | Q27860768 | ||
Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal | Q28186978 | ||
SNAREs are concentrated in cholesterol-dependent clusters that define docking and fusion sites for exocytosis | Q28364095 | ||
Peripheral neuropathy associated with monoclonal IgM anti-Pr2 cold agglutinins | Q28368055 | ||
Mice with disrupted GM2/GD2 synthase gene lack complex gangliosides but exhibit only subtle defects in their nervous system | Q28587493 | ||
Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin | Q29619130 | ||
Mice expressing only monosialoganglioside GM3 exhibit lethal audiogenic seizures. | Q30660994 | ||
Organization of ganglioside synthesis in the Golgi apparatus | Q33538124 | ||
The immunopathogenesis of Miller Fisher syndrome | Q33850688 | ||
Monoclonal antibodies raised against Guillain-Barré syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. | Q33853670 | ||
Neurotoxins affecting neuroexocytosis | Q33881286 | ||
Conus geographus toxins that discriminate between neuronal and muscle sodium channels. | Q34376153 | ||
Cerebellar neurons lacking complex gangliosides degenerate in the presence of depolarizing levels of potassium | Q34595643 | ||
Ultrastructural localization of cell membrane G M1 ganglioside by cholera toxin | Q35049788 | ||
SNARE proteins are highly enriched in lipid rafts in PC12 cells: implications for the spatial control of exocytosis. | Q35888471 | ||
Mice lacking complex gangliosides develop Wallerian degeneration and myelination defects | Q36399818 | ||
A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure | Q38314715 | ||
Ganglioside structures and distribution: Are they localized at the nerve ending? | Q39783348 | ||
Gangliosides and synaptic transmission. | Q40090012 | ||
Molecular aspects of tetanus and botulinum neurotoxin poisoning | Q40418282 | ||
Calcium-ganglioside interactions and synaptic plasticity: effect of calcium on specific ganglioside/peptide (valinomycin, gramicidin A)-complexes in mixed mono- and bilayers | Q41079344 | ||
Gangliosides mediate inhibitory effects of tetanus and botulinum A neurotoxins on exocytosis in chromaffin cells | Q42499734 | ||
Detection and prevalence of alpha-latrotoxin-like effects of serum from patients with Guillain-Barré syndrome | Q43947378 | ||
The role of monosialoganglioside GM1 in the synaptic plasticity: in vitro study on rat hippocampal slices | Q43980428 | ||
Gangliosides as receptors for biological toxins: development of sensitive fluoroimmunoassays using ganglioside-bearing liposomes | Q46269287 | ||
Effect of the mono- and tetra-sialogangliosides, GM1 and GQ1b, on long-term potentiation in the CA1 hippocampal neurons of the guinea pig. | Q46977545 | ||
The binding of botulinum toxin to membrane lipids: phospholipids and proteolipid | Q47746062 | ||
Gangliosides and sialylcholesterol as modulators of synaptic functions. | Q47825859 | ||
Isolation and biochemical characterization of a Ca2+-independent alpha-latrotoxin-binding protein | Q48059994 | ||
Designation and schematic structure of gangliosides and allied glycosphingolipids | Q48215328 | ||
Differential involvement of gangliosides versus phospholipids in the process of temperature adaptation in vertebrates. A comparative phenomenological and physicochemical study | Q48428803 | ||
Gangliosides enhance KCl-induced Ca2+ influx and acetylcholine release in brain synaptosomes | Q48659663 | ||
Lectins from Triticum vulgaris and Limax flavus are universal antagonists of botulinum neurotoxin and tetanus toxin | Q48669080 | ||
A functional role for complex gangliosides: motor deficits in GM2/GD2 synthase knockout mice | Q48695638 | ||
Gangliosides improve synaptic transmission in dentate gyrus of hippocampal rat slices | Q49135469 | ||
The subcellular localization of gangliosides in the brain | Q51212607 | ||
Non-linear summation of end-plate potentials in the frog and mouse. | Q52741737 | ||
A quantitative description of end-plate currents | Q52979944 | ||
Gangliosides affect membrane-channel activities dependent on ambient temperature. | Q53907052 | ||
Gangliosides are the binding substances in neural cells for tetanus and botulinum toxins in mice | Q57539150 | ||
Anti-GQ1b antibodies and evoked acetylcholine release at mouse motor endplates | Q61633257 | ||
Ganglioside inactivation of botulinum toxin | Q68632759 | ||
Botulinum A neurotoxin unlike tetanus toxin acts via a neuraminidase sensitive structure | Q68976927 | ||
TLC immunostaining characterization of Clostridium botulinum type A neurotoxin binding to gangliosides and free fatty acids | Q69513387 | ||
Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies | Q70514545 | ||
Interaction between Clostridium botulinum neurotoxin and gangliosides | Q71499646 | ||
The influence of exogenous gangliosides on the dynamics of the development of prolonged posttetanic potentiation | Q72586382 | ||
Serum factor in Miller-Fisher variant of Guillain-Barré syndrome and neurotransmitter release | Q72667720 | ||
Structure-based sequence alignment for the beta-trefoil subdomain of the clostridial neurotoxin family provides residue level information about the putative ganglioside binding site | Q73039693 | ||
Pre- and postsynaptic blockade of neuromuscular transmission by Miller-Fisher syndrome IgG at mouse motor nerve terminals | Q77348546 | ||
Miller Fisher anti-GQ1b antibodies: alpha-latrotoxin-like effects on motor end plates | Q78170867 | ||
P433 | issue | 16 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | neuromuscular junction | Q776995 |
autoantibody | Q785022 | ||
P304 | page(s) | 6876-6884 | |
P577 | publication date | 2002-08-01 | |
P1433 | published in | Journal of Neuroscience | Q1709864 |
P1476 | title | Complex gangliosides at the neuromuscular junction are membrane receptors for autoantibodies and botulinum neurotoxin but redundant for normal synaptic function | |
P478 | volume | 22 |
Q46558371 | Anti-disialosyl antibodies mediate selective neuronal or Schwann cell injury at mouse neuromuscular junctions. |
Q35780245 | Anti-ganglioside antibody internalization attenuates motor nerve terminal injury in a mouse model of acute motor axonal neuropathy. |
Q37207391 | Antiganglioside antibodies and their pathophysiological effects on Guillain-Barré syndrome and related disorders--a review |
Q37316102 | Association of botulinum neurotoxins with synaptic vesicle protein complexes |
Q39207459 | Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology |
Q37633113 | Botulinum Toxin Injection-Site Selection for a Smooth Shoulder Line: An Anatomical Study. |
Q58615344 | Botulinum and Tetanus Neurotoxins |
Q33869062 | Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors |
Q38224215 | Botulinum neurotoxins: genetic, structural and mechanistic insights. |
Q46981383 | Calcium signaling pathways mediating synaptic potentiation triggered by amyotrophic lateral sclerosis IgG in motor nerve terminals. |
Q89687462 | Clinical characteristics and outcomes of patients with overlapping Miller Fisher syndrome and myasthenia gravis |
Q36395728 | Clinical uses of botulinum neurotoxins: current indications, limitations and future developments |
Q92690319 | Crystal structure of botulinum neurotoxin subtype A3 cell binding domain in complex with GD1a co-receptor ganglioside |
Q41267697 | Distinct contributions of Galgt1 and Galgt2 to carbohydrate expression and function at the mouse neuromuscular junction |
Q26859917 | Emerging opportunities for serotypes of botulinum neurotoxins |
Q36611014 | Entering neurons: botulinum toxins and synaptic vesicle recycling |
Q34702285 | Evidence That Botulinum Toxin Receptors on Epithelial Cells and Neuronal Cells Are Not Identical: Implications for Development of a Non-Neurotropic Vaccine |
Q36994582 | Gangliosides as targets for autoimmune injury to the nervous system |
Q35932883 | Glycosphingolipids-sweets for botulinum neurotoxin |
Q36992893 | Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. |
Q35250681 | Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept. |
Q45301316 | Increased neurotransmitter release at the neuromuscular junction in a mouse model of polyglutamine disease |
Q35687993 | Mechanisms involved in new therapies for overactive bladder. |
Q53868907 | Overexpression of GD1a ganglioside sensitizes motor nerve terminals to anti-GD1a antibody-mediated injury in a model of acute motor axonal neuropathy. |
Q37535345 | Pathophysiological actions of neuropathy-related anti-ganglioside antibodies at the neuromuscular junction |
Q37408530 | Receptor and substrate interactions of clostridial neurotoxins |
Q79237122 | Roles of Complex Gangliosides at the Neuromuscular Junction |
Q26995291 | Sialic acids in the brain: gangliosides and polysialic acid in nervous system development, stability, disease, and regeneration |
Q47093993 | Structural basis for the unique ganglioside and cell membrane recognition mechanism of botulinum neurotoxin DC. |
Q36325534 | Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells |
Q37111379 | The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice. |
Q27004097 | The pre-synaptic motor nerve terminal as a site for antibody-mediated neurotoxicity in autoimmune neuropathies and synaptopathies |